Rối loạn cương dương: Mối quan hệ với hội chứng chuyển hóa

Current Diabetes Reports - Tập 5 - Trang 64-69 - 2005
Glenn Matfin1, Ali Jawa, Vivian A. Fonseca
1Global Clinical Research, Novartis Pharmaceuticals, East Hanover, USA

Tóm tắt

Rối loạn cương dương (ED) thường gặp hơn ở nam giới có nhiều thành phần của hội chứng chuyển hóa (một hội chứng bao gồm nhiều yếu tố nguy cơ về tim mạch và tiểu đường). ED có thể coi như một dấu hiệu nguy cơ của hội chứng chuyển hóa và các tình trạng liên quan. Bệnh nhân bị ED nên được đánh giá kỹ lưỡng về các bệnh mạch máu đi kèm. Bất kỳ yếu tố nguy cơ tim mạch nào cũng nên được điều chỉnh hoặc điều trị (ví dụ: hút thuốc, tiểu đường, huyết áp cao và rối loạn lipid máu). Rối loạn chức năng nội mô là một nguyên nhân chủ yếu liên kết nhiều khía cạnh của hội chứng chuyển hóa, đặc biệt là tiểu đường và bệnh tim mạch. Nó cũng đóng một vai trò lớn trong ED. Nguyên nhân đa yếu tố của ED, đặc biệt ở những bệnh nhân mắc hội chứng chuyển hóa, làm tăng sự phức tạp trong việc quản lý vấn đề này, vì vậy các bác sĩ lâm sàng cần nhận thức được sinh lý bệnh cơ bản để đảm bảo kết quả tốt nhất trong điều trị.

Từ khóa

#rối loạn cương dương #hội chứng chuyển hóa #yếu tố nguy cơ tim mạch #điều trị y khoa #rối loạn chức năng nội mô

Tài liệu tham khảo

NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence [no authors listed]. JAMA 1993, 270:83–90. Matfin G: New treatments for erectile dysfunction. Fertil Steril 2003, 80(suppl 4):40–45. Bacon CG, Mittleman MA, Kawachi I, et al.: Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003, 139:161–168. Data revealed a 30% reduction in risk of ED in men who were most physically active. Conversely, watching more than 20 h/wk of TV, smoking, and being overweight was associated with increased risk of ED. Guay AT, Spark RF, Bansal S, et al.: American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple’s problem-2003 update. Endocr Pract 2003, 9:77–95. Grundy SM, Brewer HB Jr, Cleeman JI, et al.: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433–438. Guven S, Kuenzi J, Matfin G: Diabetes mellitus and the metabolic syndrome. In Pathophysiology. Edited by Porth CM. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:987–1015. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359. Lue TF: Erectile dysfunction. N Engl J Med 2000, 342:1802–1813. Saigal CS: Obesity and erectile dysfunction: common problems, common solution? JAMA 2004, 291:3011–3012. Romeo JH, Seftel AD, Madhun ZT, Aron DC: Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000, 163:788–791. McCulloch DK, Campbell IW, Wu FC, et al.: The prevalence of diabetic impotence. Diabetologia 1980, 18:279–283. Kaiser FE: Erectile dysfunction in the aging man. Med Clin North Am 1999, 83:1267–1278. Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54–61. Klein R, Klein BE, Lee KE, et al.: Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996, 19:135–141. Derby CA, Mohr BA, Goldstein I, et al.: Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000, 56:302–306. Esposito K, Giugliano F, Di Palo C, et al.: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004, 291:2978–2984. Addressing risk factors for ED can reverse existing ED. Almost one third of obese men in this study had reversed their ED after exercising more and losing weight. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36–52. Richardson D, Vinik A: Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2002, 2:501–509. Solomon H, Man JW, Jackson G: Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003, 89:251–253. Levine LA, Kloner RA: Importance of asking questions about erectile dysfunction. Am J Cardiol 2000, 86:1210–1213. De Angelis L, Marfella MA, Siniscalchi M, et al.: Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia 2001, 44:1155–1160. Theuma P, Fonseca VA: Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes. Curr Drug Targets 2003, 4:477–486. Billups KL, Kaiser DR, Kelly AS, et al.: Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003, 15:231–236. Chan NN, Chan JC: Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002, 45:1609–1616. Nash DT: Insulin resistance, ADMA levels, and cardiovascular disease. JAMA 2002, 287:1451–1452. Stuhlinger MC, Abbasi F, Chu JW, et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420–1426. Lin KY, Ito A, Asagami T, et al.: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106:987–992. Mass R, Schwedhelm E, Albsmeier J, Boger RH: The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002, 7:213–225. Masuda H, Tsujii T, Okuno T, et al.: Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1730-R1738. Cartledge JJ, Eardley I, Morrison JF: Impairment of corpus cavernosal smooth muscle relaxation by glycosylated human haemoglobin. BJU Int 2000, 85:735–741. Sasaki T, Yasuda H, Maeda K, Kikkawa R: Hyperalgesia and decreased neuronal nitric oxide synthase in diabetic rats. Neuroreport 1998, 9:243–247. Veves A, Akbari CM, Primavera J, et al.: Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998, 47:457–463. Wei M, Macera CA, Davis DR, et al.: Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994, 140:930–937. Saltzman EA, Guay AT, Jacobson J: Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004, 172:255–258. Colberg SR, Stansberry KB, McNitt PM, Vinik AI: Chronic exercise is associated with enhanced cutaneous blood flow in type 2 diabetes. J Diabetes Complications 2002, 16:139–145. Jiaan DB, Seftel AD, Fogarty J, et al.: Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995, 13:369–375. Plante GE: Vascular response to stress in health and disease. Metabolism 2002, 51:25–30. Seftel AD, Vaziri ND, Ni Z, et al.: Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or e NOS. Urology 1997, 50:1016–1026. Xie Y, Garban H, Ng C, et al.: Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat. J Urol 1997, 157:1121–1126. Fink HA, Mac DR, Rutks IR, et al.: Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002, 162:1349–1360. Guay AT, Perez JB, Velasquez E, et al.: Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur Urol 2000, 38:671–676. Carson CC, Burnett AL, Levine LA, Nehra A: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002, 60:12–27. Brock GB, McMahon CG, Chen KK, et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002, 168:1332–1336. Porst H, Rosen R, Padma-Nathan H, et al.: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001, 13:192–199. DeSouza C, Parulkar A, Lumpkin D, et al.: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002, 25:1336–1339. Katz SD, Balidemaj K, Homma S, et al.: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845–851. Halcox JP, Nour KR, Zalos G, et al.: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002, 40:1232–1240. Gazzaruso C, Giordanetti S, De Amici E, et al.: Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004, 110:22–26. Erectile dysfunction can be a marker of underlying vascular disease. The presence of ED was a predictor of silent CAD in patients with apparently uncomplicated type 2 diabetes. Greenstein A, Chen J, Miller H, et al.: Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997, 9:123–126. Russell ST, Khandheria BK, Nehra A: Erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2004, 79:782–794. A survey of the current understanding of the interrelationship between ED and CVD. Jackson G: Treatment of erectile dysfunction in patients with cardiovascular disease: guide to drug selection. Drugs 2004, 64:1533–1545. Cheitlin MD, Hutter AM Jr, Brindis RG, et al.: Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999, 99:168–177.